Schizophrenia

Researchers have uncovered more evidence to support the hypothesis that lead contributes to schizophrenia onset.

Immigrant populations tend to have nearly 2 times the prevalence of psychotic disorders compared to the general population of the host country.

Patients with schizoaffective disorder who were treated with paliperidone palmitate (as monotherapy and adjunctive therapy) experienced delayed time to relapse and reduced risk of relapse compared to patients treated with placebo.

According to research published in the Proceedings of the National Academy of Sciences, patients who are sensitive to d-amphetamine have a decreased likelihood of developing ADHD or schizophrenia.

Although the first clinical case associating acromegaly with schizophrenia was reported more than 60 years ago, researchers continue to ponder the association between the 2 disorders.

When encouraging and supporting patients to quit smoking, varenicline is unlikely to increase the risk of neuropsychiatric adverse events such as suicide, depression, and aggression, even in patients with pre-existing psychiatric illness.

Creating a safer environment for clinicians and patients starts with better formalized reporting of aggressive and violent behavior, and should also include more rigorous screening and assessment for risk markers of violent behavior.

Understanding and addressing these disorders can improve the patient's mental health as well as their chronic pain and other comorbid conditions. Incorporating cognitive behavioral therapy and mindfulness-based cognitive therapy into the management of chronic pain has been shown to improve pain outcomes.

New formulation associated with delayed time to impending relapse, as well as improvements on measures of symptom severity and treatment response.

New validated assessment tools allow clinicians to better assess the level of real-life functioning in patients with schizophrenia.

Prescription-only Seroquel found in over-the-counter Nurofen packages leading to recall.

A recent study indicates that traumatic brain injury may be linked to an increased risk of developing schizophrenia.

The PANSS: a long ongoing debate in the psychiatric community revolves around its efficiency due to mathematical properties.

How is it that the placebo effect has a role in patients with schizophrenia?

Long-term treatment with antipsychotic medication apparently causes a decrease in brain volume.

Could nicotine be acting as a treatment for smoking schizophrenics?

See how the introduction of thorazine to the market changed the face of psychiatry practice.

A new Cochrane systematic review explores the effects the family interventions can have on patients with schizophrenia.

Researchers have uncovered a small genomic deletion in patients with autism spectrum disorders and schizophrenia.

Emory University researchers have identified a compound that could lead the way toward a whole new approach to schizophrenia treatment.

This symposium focused on presenting the most recent results of key projects conducted to evaluate the effects of early detection/intervention strategies.